title: The proteasome inhibitor bortezomib enhances ATRA-induced differentiation of neuroblastoma cells via the JNK mitogen-activated protein kinase pathway.
abstract: Neuroblastoma (NB) is the most common extracranial solid tumor in childhood. Differentiated human NBs are associated with better outcome and lower stage; induction of differentiation is considered to be therapeutically advantageous. All-trans retinoic acid (ATRA) has been shown to induce the differentiation of neuroblastoma (NB) cell lines. The proteasome inhibitor bortezomib inhibits cell growth and angiogenesis in NBs. Here, we investigated the synergistic effect between bortezomib and ATRA in inducing NB cell differentiation in different NB cell lines. Bortezomib combined with ATRA had a significantly enhanced antiproliferative effect. This inhibition was characterized by a synergistic increase in neuronal differentiation. At the same time, the combination therapy showed little neuronal toxicity which was assessed in primary cultures of rat cerebellar granule cells by the MTT assay, PI staining. The combination of bortezomib and ATRA triggered increased differentiation through the activation of proteins, including RARα, RARβ, RARγ, p-JNK and p21, compared with ATRA treatment alone. Using JNK inhibitor SP600125 to block JNK-dependent activity, the combination therapy-induced neuronal differentiation was partially attenuated. In addition, p21 shRNA had no effect on the combination therapy-induced neuronal differentiation. The in vivo antitumor activities were examined in human NB cell xenografts and GFP-labeled human NB cell xenografts. Treatment of human NB cell CHP126-bearing nude mice with ATRA plus bortezomib resulted in more significant tumor growth inhibition than mice treated with either drug alone. These findings provide the rationale for the development of a new therapeutic strategy for NB based on the pharmacological combination of ATRA and bortezomib.
authors.affiliation: College of Pharmaceutical Sciences, Institute of Pharmacology and Toxicology, Zhejiang University, Hangzhou, China.
authors.forename: Peihua
authors.initials: P
authors.lastname: Luo
authors.forename: Meili
authors.initials: M
authors.lastname: Lin
authors.forename: Lin
authors.initials: L
authors.lastname: Li
authors.forename: Bo
authors.initials: B
authors.lastname: Yang
authors.forename: Qiaojun
authors.initials: Q
authors.lastname: He
mesh_terms: D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology; D001897:Boronic Acids / Q000494:pharmacology*; D000069286:Bortezomib; D002454:Cell Differentiation / Q000187:drug effects*; D045744:Cell Line, Tumor; D004357:Drug Synergism; D006801:Humans; D048031:JNK Mitogen-Activated Protein Kinases / Q000378:metabolism*; D020935:MAP Kinase Signaling System; D051379:Mice; D009447:Neuroblastoma / Q000188:drug therapy* / Q000473:pathology; D011480:Protease Inhibitors / Q000494:pharmacology*; D011719:Pyrazines / Q000494:pharmacology*; D051381:Rats; D014212:Tretinoin / Q000494:pharmacology*; D023041:Xenograft Model Antitumor Assays
chemical_list: D001897:Boronic Acids; D011480:Protease Inhibitors; D011719:Pyrazines; D014212:Tretinoin; D000069286:Bortezomib; D048031:JNK Mitogen-Activated Protein Kinases
references.citation: J Neurochem. 1999 Oct;73(4):1409-21
references.pmid: 10501184
references.citation: Clin Cancer Res. 2007 Jul 1;13(13):3977-88
references.pmid: 17606732
references.citation: Clin Cancer Res. 2008 Mar 15;14(6):1649-57
references.pmid: 18347166
references.citation: Eur J Pharm Sci. 2008 Apr 23;33(4-5):415-23
references.pmid: 18337069
references.citation: Exp Neurol. 2007 Mar;204(1):317-25
references.pmid: 17214983
references.citation: J Natl Cancer Inst. 2006 Aug 16;98(16):1142-57
references.pmid: 16912267
references.citation: Cell. 1995 Dec 15;83(6):841-50
references.pmid: 8521508
references.citation: Clin Cancer Res. 2005 Apr 1;11(7):2774-80
references.pmid: 15814660
references.citation: Cancer Res. 2010 May 1;70(9):3791-802
references.pmid: 20424123
references.citation: Nat Neurosci. 2005 Jun;8(6):723-9
references.pmid: 15908947
references.citation: Oncol Rep. 2005 Jun;13(6):1139-44
references.pmid: 15870934
references.citation: Nat Rev Cancer. 2001 Dec;1(3):181-93
references.pmid: 11902573
references.citation: J Neurochem. 2002 Apr;81(2):307-13
references.pmid: 12064478
references.citation: Oncogene. 1995 Aug 3;11(3):485-91
references.pmid: 7630632
references.citation: J Biol Chem. 1995 Jun 9;270(23):13585-8
references.pmid: 7775407
references.citation: Cancer Res. 2004 Nov 1;64(21):7910-7
references.pmid: 15520197
references.citation: Blood. 2009 Apr 16;113(16):3655-65
references.pmid: 19221035
references.citation: Eur J Cell Biol. 2009 Jan;88(1):45-63
references.pmid: 18834644
references.citation: Mol Cancer Ther. 2006 Apr;5(4):962-8
references.pmid: 16648567
references.citation: Gene. 2004 Jan 21;325:1-15
references.pmid: 14697505
references.citation: Oncogene. 2007 Sep 13;26(42):6150-9
references.pmid: 17404572
references.citation: Clin Cancer Res. 2007 Mar 1;13(5):1516-22
references.pmid: 17332297
references.citation: J Neurochem. 2010 Jan;112(2):511-20
references.pmid: 19903244
references.citation: J Neurosci. 2005 Sep 14;25(37):8451-6
references.pmid: 16162927
references.citation: Curr Pharm Des. 2007;13(13):1375-400
references.pmid: 17506722
references.citation: Mol Cancer Ther. 2007 Apr;6(4):1425-32
references.pmid: 17431121
references.citation: Lancet. 2007 Jun 23;369(9579):2106-20
references.pmid: 17586306
references.citation: Cell Mol Neurobiol. 2009 May;29(3):391-401
references.pmid: 19048366
references.citation: J Neurochem. 2008 Aug;106(3):1104-16
references.pmid: 18466335
references.citation: N Engl J Med. 2008 Sep 25;359(13):1367-80
references.pmid: 18815398
references.citation: Oncogene. 1999 Sep 23;18(39):5393-402
references.pmid: 10498893
references.citation: Anesthesiology. 2010 May;112(5):1155-63
references.pmid: 20418696
references.citation: Exp Cell Res. 2009 Oct 15;315(17):3036-43
references.pmid: 19615362
references.citation: J Clin Oncol. 1999 Jul;17(7):2264-79
references.pmid: 10561284
references.citation: Clin Cancer Res. 2010 Sep 1;16(17):4478-89
references.pmid: 20630997
references.citation: Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):14807-12
references.pmid: 10611294
references.citation: Int J Mol Med. 2010 Feb;25(2):271-80
references.pmid: 20043138
references.citation: N Engl J Med. 2010 Jun 10;362(23):2202-11
references.pmid: 20558371
references.citation: Pediatr Blood Cancer. 2007 Oct 15;49(5):661-5
references.pmid: 16900483